Dr. Blackwell’s original article, “Lenacapavir for HIV PrEP: Interim Phase III Clinical Data Evaluation” has been accepted for publication in JNP–The Journal for Nurse Practitioners. The article examines the current Phase III clinical trial data of a novel antiretroviral agent that public health scientists have declared a “game changer” for HIV incidence globally. The article will be published in an upcoming issue of the journal. The abstract appears below:
Lenacapavir is an antiretroviral medication injected every six months as pre-exposure prophylaxis (PrEP) for HIV, currently undergoing Phase III clinical trials worldwide. Interim data suggest lenacapavir is highly efficacious, distinctly being the first PrEP regimen to ever show zero infections during Phase III clinical trials. Lenacapavir is being lauded as a major advancement in the eradication of HIV as a major public health threat. This article provides an overview of current clinical trial data regarding lenacapavir, discusses its current research and development, provides comparison between lenacapavir and cabotegravir, and provides implications for nurse practitioners and other clinicians regarding PrEP.
